Recent Releases
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
Recent Releases
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 9, 2023
Recent Releases
REZILIENT3 GLOBAL FIRST-LINE TRIAL OF ZIPALERTINIB LAUNCHED IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR EXON 20 INSERTION MUTATIONS
August 3, 2023